Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a £1 million investment.
Increased manufacturing demands for cell and gene therapies drive the growth of the viral vector supply market, but challenges are still to be addressed, says Symbiosis.
Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.